Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin

Trial Profile

Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Advanced breast cancer; HER2 negative breast cancer; Inflammatory breast cancer; Triple negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NeoTRIPaPDL1; NeoTRIPaPDL1 Michelangelo
  • Most Recent Events

    • 31 Jan 2024 Status changed from active, no longer recruiting to completed.
    • 24 Oct 2023 Results assessing efficacy of of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer presented at the 48th European Society for Medical Oncology Congress
    • 14 Feb 2023 Planned End Date changed from 1 Oct 2022 to 1 Jan 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top